Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis

Rheumatology International

Volumn 26, Issue 2, 2005, Pages 157-161

  Tekeoglu I ^a   Adak, B ^a   Budancamanak, M ^a   Demirel, A ^a   Ediz, L ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

1 hydroxyvitamin D3; Calcitonin; Cyclic therapy; Osteoporosis; Treatment

Indexed keywords

ALFACALCIDOL; CALCIUM; CREATININE; SALCATONIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BONE DENSITY; BONE MASS; BURNING SENSATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; EVALUATION; FEMALE; FEMUR; FOLLOW UP; HUMAN; LUMBAR VERTEBRA; NAUSEA; PAIN ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SYSTEMIC DISEASE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; AGED; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CALCIUM; CHOLECALCIFEROL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PAIN;

EID: 28844485113     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-004-0549-7     Document Type: Article

References (27)

1. Munoz BY, Domingo AR, Minguella JF (2000) Calcitonin, osteoporosis treatment and prevention. Drugs of Today 36(Suppl D):13-25
2. Melton LJ, Chrichilles EA, Cooper C et al (1992) Perspective. How many women have osteoporosis. J Bone Miner Res 7:1005-1010
3. Khan A (2003) Advances in osteoporosis therapy 2003 update of practical guidelines. Can Fam Physician 49:441-7
4. Reid IR (2002) Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety. Expert Opin Drug Saf 1(1):93-107
5. Seeman E, Allen T (1989): Risk factors for osteoporosis. Aust N Z J Med 19:69-75
6. Consensus development conference (1993) Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 94:646-650
7. Meunier PJ (1992) Calcitonin and bone diseases. Lancet 25(339):1065
8. Ryan PJ, Harrison R, Blake GM et al (1992) Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 99:325-328
9. Overgaad K, Hansen MA, Jensen SB (1992) Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. BMJ 5(305):556-561
10. Overgaad K, Lindsay R, Christiansen C (1995) Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of 2-year study. Clin Ther 17:660-665
11. Beck Jensen JE, Thamsborg G, Kollerup G et al (1995) Effect of nasal salmon calcitonin in established osteoporosis. Bone 16(Suppl):198S
12. Flicker L, Larkins RG, Hooper JL et al (1995) Nandrolone deaconate and intranasal calcitonin as therapy in established osteoporosis. Bone 16 (Suppl):164
13. Thamsborg G, Storm TL, Sykulsky R et al (1991) Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 48:302-307
14. Srivastava M, Deal C (2002) Osteoporosis in elderly: prevention and treatment. Clin Geriatr Med.18(3):529-555
15. Eichner SF, Lloyd KB, Timpe EM (2003) Comparing therapies for postmenopausal osteoporosis prevention and treatment. Ann Pharmacother 37(5):711-724
16. Abellan Perez M, Bayina Garcia FJ, Calabozo M et al (1995) Multicentre comparative study of synthetic salmon calcitonin administered nasally in the treatment of established postmenopausal osteoporosis. Ann Med Int 12:12-26
17. Gennari C, Agnusdei D, Camporeale A (1993) Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis. Osteoporosis Int 3(Suppl 1):208-210
18. Gennari C, Agnusdei D, Camporeale A (1993) Long-term treatment with calcitonin in osteoporosis. Horm Metab Res 25:484-485
19. Munoz TM, Mezquita RP (2000) Calcitonin. Drugs of Today 36(Suppl D):1-11
20. Maini M, Bozzi M, Brignoli E et al (1995) Calcitonin nasal spray in osteoporosis: short and long-term effects of various treatment regimens. Minerva Med 86:121-127
21. Fioretti P, Gambacciani M, Taponeco F et al (1992) Effect of continuous and cyclic nasal calcitonin administration in ovariactomized women. Maturitas 15:225-232
22. Stuart L, Silverman SL, Chesnut C et al (1998) Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture (VF) in established osteoporosis and has continuous efficacy with prolonged treatment: Accrued 5 year worldwide data of the PROOF study. 2nd joint meeting American Society Bone and Mineral Research Abstract, San Francisco
23. Takahashi S, Goldring S, Katz M (1995) Down-regulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 95:167-171
24. Gennari C (2002) Analgesic effect of calcitonin in osteoporosis. Bone 30(5):675-705
25. Lyritis GF, Tsakalatos N, Magiasis B et al (1991) Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double blind-placebo controlled study. Calcif Tissue Int 49:369-372
26. Pontiroli AE, Pajeta E, Scaglia L et al (1994). Analgesic effect of intranasal and intramuscular salmon calcitonin in postmenopausal osteoporosis: a double-blind, double-placebo study. Aging Clin Exp Res 6:459-463
27. Silverman SL, Azria M. (2002) The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 13(11):858-867